Can risperidone worsen pre‑existing atrioventricular (AV) block, such as first‑degree or second‑degree heart block?

Can Risperidone Worsen Heart Block?

Risperidone does not directly worsen atrioventricular (AV) block and is not contraindicated in patients with first-degree or second-degree heart block, as it does not slow AV nodal conduction like beta-blockers, calcium channel blockers, or digoxin. 1

Mechanism of Cardiac Effects

Risperidone's primary cardiac effect is QT interval prolongation through blockade of the rapid component of the delayed rectifier potassium current (IKr/HERG channel), not through effects on AV nodal conduction. 2

• Risperidone blocks IKr with an IC50 of 261 nM at clinically relevant concentrations, producing Class III antiarrhythmic-like effects that prolong ventricular repolarization rather than slowing AV conduction. 2
• In elderly patients, risperidone prolonged QT interval but had no significant effect on QT dispersion and was not associated with sudden death or ventricular arrhythmia during follow-up. 3

Key Distinction from AV Nodal Blocking Agents

Risperidone differs fundamentally from medications that are contraindicated in AV block:

• Beta-blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), and digoxin have negative dromotropic effects that slow AV nodal conduction and are contraindicated in AV block greater than first-degree. 1, 4
• These agents prolong the PR interval and AV nodal refractory periods, which can precipitate higher-degree block in susceptible patients. 4
• Risperidone does not share this mechanism and does not affect the AV node in the same manner. 2

Clinical Management Algorithm

For Patients with First-Degree AV Block (PR >200 ms):

Risperidone can be used safely if:

• PR interval is <300 ms and patient is asymptomatic 5
• No evidence of structural heart disease 5
• QRS duration is normal 5

Exercise caution if:

• PR interval ≥300 ms with symptoms resembling pacemaker syndrome (fatigue, exercise intolerance, dyspnea) 5
• Coexisting bifascicular block or bundle branch block, which increases risk of progression to complete heart block 5
• Neuromuscular diseases (myotonic dystrophy, Kearns-Sayre syndrome) where unpredictable progression can occur 5

For Patients with Second-Degree AV Block:

• Type I (Wenckebach/Mobitz I): Usually occurs at the AV node level and has benign prognosis; risperidone is not contraindicated as it does not worsen AV nodal conduction. 1
• Type II (Mobitz II): Block is typically infra-Hisian with poor prognosis and risk of progression; while risperidone does not directly worsen the block, these patients require close cardiac monitoring regardless of medication choices. 1

Important Caveats and Monitoring

The primary cardiac risk with risperidone is QT prolongation and potential for torsades de pointes, not worsening of AV block:

• Monitor for QT prolongation, especially in patients who are CYP2D6 poor metabolizers or taking CYP2D6 inhibitors, as these increase risperidone levels. 2, 6
• The ABCB1 C3435T polymorphism (CT or TT genotypes) is associated with longer QTc intervals on risperidone. 6
• Avoid combining risperidone with other QT-prolonging medications. 2

Avoid concurrent use of true AV nodal blocking agents (beta-blockers, verapamil, diltiazem, digoxin) in patients with pre-existing AV block, as these medications—not risperidone—are what can precipitate higher-degree block. 1, 5

FDA Labeling Considerations

The FDA label for risperidone warns of cardiovascular deaths in elderly patients with dementia-related psychosis, primarily from heart failure and sudden death, but does not specifically contraindicate use in AV block. 7 The cardiac dysrhythmias mentioned in the context of Neuroleptic Malignant Syndrome are related to autonomic instability, not direct effects on AV conduction. 7

Bottom Line for Clinical Practice

Risperidone can be prescribed to patients with first-degree or stable second-degree Type I AV block without concern for worsening the conduction abnormality itself. The focus should be on monitoring for QT prolongation and avoiding combination with medications that truly do slow AV nodal conduction (beta-blockers, calcium channel blockers, digoxin), which are the agents that carry precautions against use in AV block greater than first-degree. 1, 5, 2